RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

This Phase II study is testing RC18 (telitacicept), a drug that reduces overactive immune responses, as a treatment for people with relapsing-remitting multiple sclerosis (RRMS) — the most common form of MS characterized by episodes of worsening symptoms followed by partial recovery. **You may be eligible if...** - You are between 18 and 55 years old - You have been diagnosed with relapsing-remitting multiple sclerosis (RRMS) based on 2017 McDonald criteria - You have had at least one relapse in the past year, or two relapses in the past two years, or active lesions on recent brain MRI - Your neurological symptoms have been stable for at least 30 days before joining the study - Your disability score (EDSS) is 5.5 or lower **You may NOT be eligible if...** - You cannot have an MRI or are allergic to MRI contrast agents - You have another autoimmune disease in addition to MS - You have active infections or a history of certain serious infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.